Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
Authors:
- Keiichi FujiwaraKFKeiichi Fujiwara
- Hiroyuki FujiwaraHFHiroyuki Fujiwara
- Hiroyuki YoshidaHYHiroyuki Yoshida
- Toyomi SatohTSToyomi Satoh
- Kan YonemoriKYKan Yonemori
- Shoji NagaoSNShoji Nagao
- Takashi MatsumotoTMTakashi Matsumoto
- Hiroaki KobayashiHKHiroaki Kobayashi
- Hughes BourgeoisHBHughes Bourgeois
- Philipp HarterPHPhilipp Harter
- Anna Maria MosconiAMAnna Maria Mosconi
- Isabel Palacio VazquezIVIsabel Palacio Vazquez
Open Access
- 1 January 2021
- journal article
- research article
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (5) , e82
Abstract
Fujiwara K, et al. J Gynecol Oncol. 2021 Jul;32(5):e82. https://doi.org/10.3802/jgo.2021.32.e82Keywords
Funding Information
- Merck Sharp and Dohme United Kingdom
- F. Hoffmann-La Roche
This publication has 15 references indexed in Scilit:
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine, 2018
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Clinical statistics of gynecologic cancers in JapanJournal of Gynecologic Oncology, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialThe Lancet Oncology, 2016
- Diagnosis and Management of Ovarian Cancer.2016
- European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015International Journal of Gynecological Cancer, 2015
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Pharmaceutical CompaniesInternational Journal of Gynecological Cancer, 2010